| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 430,0 k € | -4.5% | 450,3 k € | -5.0% | 474,2 k € | +1.7% | 466,3 k € | +8.3% | 430,8 k € | +18.7% | 362,8 k € | +33.8% | 271,2 k € | +10.5% | 245,5 k € | +67.4% | 146,7 k € | +23.8% | 118,5 k € | +3.3% | 114,7 k € | |
| EBITDA | 276,4 k € | -10.4% | 308,6 k € | -17.9% | 376,1 k € | +5.6% | 356,2 k € | +14.6% | 310,7 k € | +27.7% | 243,3 k € | +65.8% | 146,7 k € | +7.7% | 136,2 k € | +255.9% | 38,3 k € | +13.7% | 33,7 k € | +63.1% | 20,6 k € | |
| Operating profit | 203,7 k € | -15.5% | 240,9 k € | -23.4% | 314,5 k € | +6.1% | 296,3 k € | +17.4% | 252,4 k € | +43.2% | 176,3 k € | +140.3% | 73,4 k € | +29.9% | 56,5 k € | +1295.9% | -4,7 k € | +2.2% | -4,8 k € | +82.5% | -27,7 k € | |
| Profit/loss | 188,6 k € | -1.9% | 192,3 k € | -34.9% | 295,5 k € | +56.1% | 189,4 k € | +24.8% | 151,8 k € | +3.6% | 146,4 k € | +640.5% | 19,8 k € | -40.1% | 33,0 k € | +10166.2% | 321,4 € | -66.5% | 959,3 € | +104.5% | -21,1 k € | |
| Equity | 1,2 M € | +12.2% | 1,1 M € | +17.8% | 896,0 k € | +49.2% | 600,5 k € | +46.1% | 411,1 k € | +58.5% | 259,4 k € | +95.1% | 132,9 k € | +17.5% | 113,2 k € | +275.3% | 30,2 k € | +1.1% | 29,8 k € | +3.3% | 28,9 k € | |
| Total assets | 5,7 M € | +60.6% | 3,5 M € | +1.9% | 3,5 M € | +2.1% | 3,4 M € | +2.4% | 3,3 M € | -1.3% | 3,4 M € | -0.6% | 3,4 M € | +20.4% | 2,8 M € | +401.3% | 558,3 k € | -5.5% | 591,0 k € | +13.2% | 522,1 k € | |
| Cash | 104,7 k € | -37.0% | 166,1 k € | +75.2% | 94,8 k € | +60.4% | 59,1 k € | +1484.3% | 3,7 k € | -81.6% | 20,3 k € | +108.5% | 9,8 k € | -65.7% | 28,4 k € | +300.7% | 7,1 k € | -73.0% | 26,3 k € | -31.7% | 38,5 k € | |
| Debts | 4,4 M € | +81.3% | 2,4 M € | -3.7% | 2,5 M € | -8.1% | 2,8 M € | -4.4% | 2,9 M € | -6.3% | 3,1 M € | -4.3% | 3,2 M € | +20.4% | 2,7 M € | +410.4% | 525,5 k € | -5.4% | 555,2 k € | +13.0% | 491,2 k € | |
| Staff | 2,3 | 2,8 | 1,9 | 2,3 | 2,5 | 2,5 | 2,9 | — | — | 2,6 | 1,5 | |||||||||||
Private limited company · Oudenaarde · incorporated on 23/07/2013 · 2,3 ETP
Private limited company profitable and well capitalised. Cash position declining (-37.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Conrad Pharma is a Private limited company incorporated in 2013. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Oudenaarde. It employs on average 2,3 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.